Pfizer’s Xeljanz Benefits From Biologic Switching In Rheumatoid Arthritis, According To Spherix Global Insights

Spherix Global Insights reveals that Xeljanz is carving a niche as a popular switch-to-agent in second and later lines of biologic/JAK therapy for the treatment of rheumatoid arthritis (RA).  Specifically, Xeljanz accounts for 16%… http://www.prnewswire.com/news-releases/pfizers-xeljanz-benefits-from-biologic-switching-in-rheumatoid-arthritis-according-to-spherix-global-insights-300267685.html